… 2025, Ferring Pharmaceuticals announced U.S. Food and Drug Administration ( … expects to submit an New Drug Application (NDA) with the … July 2025, Pfizer and Astellas Pharma announced topline results from … FDA extended the Prescription Drug User Fee Act action …

Myrbetriq® (mirabegron) Case Name: Astellas Pharma Inc. v. Zydus, Inc., … 30, 2025) (Bataillon, J.) Drug Product and Patent(s)-in … . Why Defendants Prevailed: Astellas argued that the Federal … that theory. “Indeed, Astellas is defending against an obviousness …

… landscape. Stringent regulations regarding drug approval, pricing, and post … Companies Novartis AG, Sanofi, Astellas Pharma Inc., Asahi Kasei Corporation, … Transplant Therapeutics Market Segmentation By Drug Class: Calcineurin Inhibitors, Interleukin …

… for review the supplemental New Drug Applications (sNDAs) for Braftovi … (enzalutamide) – In April 2023, Astellas Pharma and Pfizer announced that Xtandi … vaccine's or drug';s efficacy and, … of a vaccine or drug, including the authorization or approval …

… Advanced Therapy (RMAT) and orphan drug designations, as well as the … 3. OCU410ST previously received orphan drug designations for the treatment of … recent years—Apellis Pharmaceuticals’ Syfovre® (pegcetacoplan injection) and Astellas Pharma’s Izervay™ ( …

… consumer marketing for Endo Pharmaceuticals, drew positive response at … MediaPost’s recent Pharma & Health Brand … clients include Astellas Pharma’s Super Bowl-advertised drug for hot … for women’s health pharma firm Organon, noted, however …

… of Emerging Neuroendocrine Prostate Cancer Drugs Competitive Intelligence Analysis: SWOT analysis … Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly …

… they can be targeted by drugs or supplements,” Wubben said. Glutamine … Medical. Lyssiotis has consulted for Astellas Pharmaceuticals, Odyssey Therapeutics, Third Rock Ventures …

A recent study presented at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists in Long Beach, CA, has delineated a series of parameters associated with faster geographic atrophy (GA) growth, including nonsubfoveal GA location, …

… U.S. and EU orphan drug designations as well as Fast … the U.S. Food and Drug Administration (FDA) remain ongoing. This … . The announcement was made with Astellas Pharma U.S. Inc. XTANDI is … the U.S. Food and Drug Administration regarding a phase 3 …